COVID-19 vaccine effectiveness studies in Nigeria: Quo vadis?
- Akande, Oluwatosin Wuraola
- Igumbor, Ehimario Uche
- Elimian, Kelly Osezele
- Ohonsi, Cornelius Ehizokhai
- Nwozor, Lilian
- Oden, Okanke
- Ekpenyong, Emmanuel Nsa
- Ndodo, Nnaemeka
- Ike, Ifeanyi F
- Egede, Magdalene
- Nwachukwu, William
- Onoja, Amedu M
- Fofah, Jenson Gawain
- Azi, Reuben Ishiaku
- Ochu, Chinwe L
- Adetifa, Ifedayo M
DOIAbstract
The “lickety-split” development of COVID-19 vaccines 326 days from when the SARS-COV-2 virus was first sequenced is indeed one of the public health successes of the 21st century. Particularly because an 18-month target was initially considered reasonable, and having achieved this success, a “moonshot” goal to ensure that a vaccine is available within 100 days after the next pandemic pathogen is recognized has been set [1]
Add to ORKG